https://charts.traderzeitung.de/phases/US62855J1043 string(1395) "{"isin":"US62855J1043","name":"Myriad Genetics Inc","stock_id_xnas":7874466,"stock_id_xnys":null,"generated_at":"2026-08-09 09:13:00","days":[{"date":"2026-08-05","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":3.155,"close_at":"2026-08-05 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-06","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":3.175,"close_at":"2026-08-06 21:59:00","complete":true,"perf_pct":0.6339},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-07","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":3.255,"close_at":"2026-08-07 21:59:00","complete":true,"perf_pct":2.5197},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"

Myriad Genetics Aktie News & Nachrichten

[WKN: 897518 | Symbol: MYGN]

Realtimekurs

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

10J

Alles

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Myriad Genetics gefunden werden.

Myriad Genetics Nachrichtenticker öffnen

MT Newswires 26.05.2026 22:23 Uhr

Myriad Genetics führt Prolaris + AI Prostatakrebs-Test ein

04:23 PM EDT, 05/26/2026 (MT Newswires) -- Myriad Genetics (MYGN) wird den Prolaris + AI Prostatakrebs-Test Ende Mai einführen, teilte das Unternehmen